Advances in the research of mechanisms related to obesity combined with thyroid carcinoma

doi:10.3877/cma.j.issn.1674-0793.2023.04.017

Abstract

Abstract:

In recent years, the incidence of thyroid carcinoma has been increasing year by year, and the number of obese people worldwide is also increasing in parallel. Studies have identified obesity as a possible risk factor for thyroid cancer, in which interleukin 6, tumor necrosis factor alpha, leptin, adiponectin, estrogen and thyroid stimulating hormone are all associated with the development of thyroid carcinoma, while metabolic dysregulation such as insulin resistance and dysbiosis of intestinal flora also promote the development of thyroid carcinoma by indirect or direct effects. The progression of thyroid carcinoma is also facilitated by metabolic disorders such as insulin resistance and intestinal flora. Nevertheless, the pathogenic mechanisms associated with obesity combined with thyroid carcinoma are still unclear. In this review, we have searched the relevant literature in the past 5 years to describe the mechanisms of thyroid cancer in combination with obesity, in order to provide reference for future basic and clinical research.

Key words: Thyroid neoplasms, Obesity, Cytokines, Metabolism, Mechanism

Yonghao Li, Xuefei Gao, Tiantian Guo, Jin Zhang, Caizhen Zhang, Jing Liu. Advances in the research of mechanisms related to obesity combined with thyroid carcinoma[J]. Chinese Archives of General Surgery(Electronic Edition), 2023, 17(04): 311-315.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhptwkxwx.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0793.2023.04.017

https://zhptwkxwx.cma-cmc.com.cn/EN/Y2023/V17/I04/311

References 38

[1]	Demetriou E, Fokou M, Frangos S, et al. Thyroid nodules and obesity[J]. Life (Basel). 2023, 13(6): 1292.
[2]	Kitahara CM, McCullough ML, Franceschi S, et al. Anthropometric factors and thyroid cancer risk by histological subtype: pooled analysis of 22 prospective studies[J]. Thyroid, 2016, 26(2): 306-318.
[3]	Fussey JM, Beaumont RN, Wood AR, et al. Does obesity cause thyroid cancer? A mendelian randomization study[J]. J Clin Endocrinol Metab, 2020, 105(7): e2398–2407.
[4]	Zhao S, Jia X, Fan X, et al. Association of obesity with the clinicopathological features of thyroid cancer in a large, operative population: A retrospective case-control study[J]. Medicine (Baltimore), 2019, 98(50): e18213.
[5]	Wang H, Wang P, Wu Y, et al. Correlation between obesity and clinicopathological characteristics in patients with papillary thyroid cancer: A study of 1 579 cases: A retrospective study[J]. PeerJ, 2020, 8: e9675.
[6]	Lee J, Lee CR, Ku CR, et al. Association between obesity and BRAFV600E mutation status in patients with papillary thyroid cancer[J]. Ann Surg Oncol, 2015, 22 Suppl 3: S683-S690.
[7]	Cnop M, Foufelle F, Velloso LA. Endoplasmic reticulum stress, obesity and diabetes[J]. Trends Mol Med, 2012, 18(1): 59–68.
[8]	Zheng R, Chen G, Li X, et al. Effect of IL-6 on proliferation of human thyroid anaplastic cancer stem cells[J]. Int J Clin Exp Pathol, 2019, 12(11): 3992-4001.
[9]	Lumachi F, Basso SM, Orlando R. Cytokines, thyroid diseases and thyroid cancer[J]. Cytokine, 2010, 50(3): 229-233.
[10]	Couto JP, Daly L, Almeida A, et al. STAT3 negatively regulates thyroid tumorigenesis[J]. Proc Natl Acad Sci USA, 2012, 109(35): E2361-E2370.
[11]	Sethi JK, Hotamisligil GS. Metabolic messengers: tumour necrosis factor[J]. Nat Metab, 2021, 3(10): 1302-1312.
[12]	Kobawala TP, Trivedi TI, Gajjar KK, et al. Significance of TNF-α and the adhesion molecules: L-Selectin and VCAM-1 in papillary thyroid carcinoma[J]. J Thyroid Res, 2016: 8143695.
[13]	Zhang N, Wang Q, Tian Y, et al. Expressions of IL-17 and TNF-α in patients with Hashimoto’s disease combined with thyroid cancer before and after surgery and their relationship with prognosis[J]. Clin Transl Oncol, 2020, 22(8): 1280-1287.
[14]	Dossus L, Franceschi S, Biessy C, et al. Adipokines and inflammation markers and risk of differentiated thyroid carcinoma: the EPIC study[J]. Int J Cancer, 2018, 142(7): 1332-1342.
[15]	Gheorghe DC, Stanciu MM, Zamfirescu A, et al. TNF-α may exert different antitumor effects in response to radioactive iodine therapy in papillary thyroid cancer with/without autoimmune thyroiditis[J]. Cancers (Basel), 2021, 13(14): 3609.
[16]	Haase J, Weyer U, Immig K, et al. Local proliferation of macrophages in adipose tissue during obesity-induced inflammation[J]. Diabetologia, 2014, 57(3): 562–571.
[17]	Dogan R, Dogan EE, Guler EM, et al. Oxidative stress values of tumor core, edge, and healthy thyroid tissue in thyroid masses[J]. Eur Arch Otorhinolaryngol, 2021, 278(8): 2953–2960.
[18]	Xing M. Oxidative stress: A new risk factor for thyroid cancer[J]. Endocr Relat Cancer, 2012, 19(1): C7–C11.
[19]	Bétry C, Challan-Belval MA, Bernard A, et al. Increased TSH in obesity: evidence for a BMI-independent association with leptin[J]. Diabetes Metab, 2015, 41(3): 248-251.
[20]	Rehem RA, Elwafa WA, Elwafa RA, et al. Study of serum leptin in well-differentiated thyroid carcinoma: correlation with patient and tumor characteristics[J]. World J Surg, 2014, 38(10): 2621-2627.
[21]	Cheng SP, Chi CW, Tzen CY, et al. Clinicopathologic significance of leptin and leptin receptor expressions in papillary thyroid carcinoma[J]. Surgery, 2010, 147(6): 847-853.
[22]	Uddin S, Bavi P, Siraj AK, et al. Leptin-R and its association with PI3K/AKT signaling pathway in papillary thyroid carcinoma[J]. Endocr Relat Cancer, 2010, 17(1): 191-202.
[23]	Park JW, Han CR, Zhao L, et al. Inhibition of STAT3 activity delays obesity-induced thyroid carcinogenesis in a mouse model[J]. Endocr Relat Cancer, 2016, 23(1): 53-63.
[24]	Kim WG, Cheng SY. Mechanisms linking obesity and thyroid cancer development and progression in mouse models[J]. Horm Cancer, 2018, 9(2): 108-116.
[25]	Dalamaga M, Diakopoulos KN, Mantzoros CS. The role of adiponectin in cancer: A review of current evidence[J]. Endocr Rev, 2012, 33(4): 547-594.
[26]	Zhou Y, Yang Y, Zhou T, et al. Adiponectin and thyroid cancer: insight into the association between adiponectin and obesity[J]. Aging Dis, 2021, 12(2): 597-613.
[27]	Mitsiades N, Pazaitou-Panayiotou K, Aronis KN, et al. Circulating adiponectin is inversely associated with risk of thyroid cancer: in vivo and in vitro studies[J]. J Clin Endocrinol Metab, 2011, 96(12): E2023-E2028.
[28]	Kwon H, Park SE, Yun JS, et al. Serum Adiponectin and progranulin level in patients with benign thyroid nodule or papillary thyroid cancer[J]. Endocrinol Metab (Seoul), 2020, 35(2): 396-406.
[29]	Finck BN, Johnson RW. Tumor necrosis factor(TNF)-alpha induces leptin production through the p55 TNF receptor[J]. Am J Physiol Regul Integr Comp Physiol, 2000, 278(2): R537-R543.
[30]	He Y, Lu L, Wei X, et al. The multimerization and secretion of adiponectin are regulated by TNF-alpha[J]. Endocrine, 2016, 51(3): 456-468.
[31]	Liu J, Xu T, Ma L, et al. Signal pathway of estrogen and estrogen receptor in the development of thyroid cancer[J]. Front Oncol, 2021, 11: 593479.
[32]	Xing M. Molecular pathogenesis and mechanisms of thyroid cancer[J]. Nat Rev Cancer, 2013, 13(3): 184-199.
[33]	Xu N, Liu H, Wang Y, et al. Relationship between insulin resistance and thyroid cancer in Chinese euthyroid subjects without conditions affecting insulin resistance[J]. BMC Endocr Disord, 2022, 22(1): 58.
[34]	Vella V, Malaguarnera R. The emerging role of insulin receptor isoforms in thyroid cancer: clinical implications and new perspectives[J]. Int J Mol Sci, 2018, 19(12): 3814.
[35]	Manzella L, Massimino M, Stella S, et al. Activation of the IGF Axis in thyroid cancer: implications for tumorigenesis and treatment[J]. Int J Mol Sci, 2019, 20(13): 3258.
[36]	高琳, 王婧颖, 马素芳, 等. 肠道菌群与甲状腺相关疾病关系的研究进展[J]. 山西医科大学学报, 2023, 54(5): 707-710.
[37]	Watanabe H, Katsura T, Takahara M, et al. Plasma lipopolysaccharide binding protein level statistically mediates between body mass index and chronic microinflammation in Japanese patients with type 1 diabetes[J]. Diabetol Int, 2020, 11(3): 293-297.
[38]	Park S, Willingham MC, Qi J, et al. Metformin and JQ1 synergistically inhibit obesity-activated thyroid cancer[J]. Endocr Relat Cancer, 2018, 25(10): 865-877.

Please choose a citation manager

Content to export